-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, as pharmaceutical giants successively announced the second quarter and first half of 2021 financial report data, most companies have achieved growth in drug sales
The resilience of the pharmaceutical giant's drug sales rebound even surprised market experts
More than half of the large pharmaceutical companies reported that compared with the second quarter of 2020, revenues in the second quarter of 2021 during the same period increased by more than 15%
New crown therapy helps rebound
The most significant revenue growth is the company that has developed the new crown therapy
Another type of company is Moderna, whose vaccine sales accounted for almost all of its growth, increasing from US$67 million in the second quarter of 2020 to US$4.
The only pharmaceutical company whose revenue has dropped significantly is about to usher in a large amount of revenue
Different areas of rebound
Although the overall data shows that pharmaceutical giants are rebounding in drug sales, some therapeutic areas have been slower to respond
On the other hand, vaccines are rapidly recovering
In terms of doctors' medication, such as immuno-oncology drugs, it also showed steady growth in the second quarter
Not all cancer drug sales rebounded equally
Looking forward to the third quarter, although the spread of delta mutation has brought uncertainty, the pharmaceutical industry’s strong innovation and R&D pipeline strength will drive long-term growth
